Historically, the primary focus of cancer research has been molecular and clinical studies of
a few essential pathways and genes. Recent years have seen the rapid accumulation of …

Cancer is driven by genetic change, and the advent of massively parallel sequencing has
enabled systematic documentation of this variation at the whole-genome scale,–. Here we …

Gene editing has great potential in treating diseases caused by well-characterized
molecular alterations. The introduction of clustered regularly interspaced short palindromic …

Acquired drug resistance to anticancer targeted therapies remains an unsolved clinical
problem. Although many drivers of acquired drug resistance have been identified,,–, the …

Cancer driver events refer to key genetic aberrations that drive oncogenesis; however, their
exact molecular mechanisms remain insufficiently understood. Here, our multi-omics pan …

Background Accumulated evidence supports the existence of sex-associated differences in
immune systems. Understanding the role of sex in immune-related adverse events (irAEs) is …

Understanding the exact molecular mechanisms involved in the aetiology of epileptogenic
pathologies with or without tumour activity is essential for improving treatment of drug …

Cytogenetics has long represented a critical component in the clinical evaluation of
hematologic malignancies. Chromosome banding studies provide a simultaneous snapshot …

The integration of whole genome sequencing (WGS) into all aspects of modern medicine
represents the next step in the evolution of healthcare. Using this technology, scientists and …

Whole genome sequencing (WGS) is becoming the preferred method for molecular genetic
diagnosis of rare and unknown diseases and for identification of actionable cancer drivers …